As per a report by P&S Intelligence, the size of the nuclear imaging equipment market was USD 2,651.3 million in 2021, and it will grow at a rate of 6% in the years to come, for reaching USD 4,463.7 million by 2030.
For example, the SPECT/CT system allows specific localization and improved specificity of the data delivered by a CT scan, in the case of skeletal inspection. Numerous hospitals are progressively switching from standalone to hybrid equipment because of these advantages.
Some of the current progressions in imaging technology that are applicable to radionuclide therapy include:
A main benefit of PET/MRI over PET/CT is an improved soft tissue contrast, which is essential for treatment planning, dosimetry, and post-radionuclide therapy assessment. It is beneficial since it offers the concurrent co-registration of MR descriptions, which is significant for precise dosimetry.
Also, numerous nations, chiefly the U.S. and those in Europe, are making a eagerness assessment framework for effective and smart ways of putting to use radio drugs, so as to offer safe and effective treatments. Therefore, most hospitals are concentrating on the therapy for cancer patients, encouraged by its high efficiency and few side-effects. Nuclear imaging is by now making a main contribution in detecting the area of spread of the cancer in the body.
Doctors can rapidly compare scans to precisely track the ailment's course, with the usage of integration of data. Clinicians now wish easy access to comprehensive data on patient diagnostic history, for developing a treatment plan that would be fruitful along with being cost-effective.
It is because of the increasing aging population, the demand for nuclear imaging equipment will be om the rise in the future.
